Plerixafor (Mozobil), formerly known as AMD3100 (Genzyme, Cambridge, Mass, USA), is a CXCR4 antagonist which has been recently approved for PBSC mobilization in multiple myeloma (MM) and non-Hodgkin's lymphoma patients (NHL) undergoing ASCT. The gene discussed is CXCR4; the disease is non-Hodgkin lymphoma.